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Abstract 
Background: Diabetes is a disease of the endocrine system characterized by hyperglycemia, 
which can lead to multiple microvascular and macrovascular complications. Successful control 
of blood glucose levels can decrease associated complications. 
Objective: This study evaluated the effectiveness of nutrition and lifestyle interventions in 
people diagnosed with type 2 diabetes. 
Methods: A retrospective study reviewed laboratory data of individuals that attended the St. 
Joseph Mercy Center for Diabetes education program. HbA1c and lipid value were evaluated to 
determine the effectiveness of the program. 
Results: Baseline HbA1c for all groups was 8.33%. Post-Program HbA1c was 6.70%, showing a 
1.63% (p<0.0001) reduction from Baseline to Post-Program. There was a significant reduction in 
HbA1c of 1.4% (p<0.0001) for all groups from Baseline to 2-years Post-Program. Lipid levels 
did not show a significant change from Baseline to Post-Program, however, lipid levels reached 
target levels and continued to improve through 2-years Post-Program.  
Conclusion: This study supports the effectiveness of the St. Joseph Mercy Center for Diabetes 
education program for lowering HbA1c levels and maintaining HbA1c and lipid levels within the 
recommended ranges.  
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Chapter 1: Introduction 
 
Background 
      It is well known that diabetes mellitus (DM) is a growing epidemic. As of 2010, 
approximately 25.8 million people living in the United States were affected by diabetes, which is 
roughly 8.3% of the total US population. Nearly 19 million people are diagnosed with diabetes; 
this includes gestational diabetes (GDM), type 1 diabetes (T1DM), and type 2 diabetes 
(T2DM)(Center for Disease Control and Prevention [CDC], 2011).  Type 2 diabetes mellitus 
accounts for approximately 90-95% of the diagnosed cases of diabetes (CDC, 2011). Along with 
this data, it is estimated that approximately seven million people are living with undiagnosed 
diabetes, while another estimated 79 million people have pre-diabetes (CDC, 2011). The current 
cost of medical expense is approximately 2.3 times higher in individuals with diabetes when 
compared to individuals without diabetes because of the associated complications (CDC, 2011).  
The greater burden of medical costs occurs with individuals diagnosed with pre-diabetes and 
T2DM (CDC, 2011). The cost of diabetes is likely to grow as more people are diagnosed with 
both pre-diabetes and T2DM. An effective Diabetes Self-Management Education program 
(DSMEP) can help lower the burden of cost that diabetes has on the health care system by 
helping to provide essential skills and education necessary to maintain optimal glycemic control 
and minimize related complications (American Diabetes Association [ADA], 2011). 
What Is Diabetes?      
      Diabetes mellitus is a disease of the endocrine system, characterized by hyperglycemia 
(McCance, 2009). During digestion, consumed food is broken down into smaller units, which 
facilitates the absorption of nutrients and their utilization by the body (McCance, 2009). 
Carbohydrates are digested into the simplest form of sugar, known as glucose. Glucose circulates 
through the bloodstream and is distributed to cells throughout the body, including but not limited 
2 
 
to the hepatic, skeletal, and the adipose tissue, where it is used as energy (McCance, 2009). 
Insulin, an anabolic peptide hormone produced by the beta cells of the pancreas and secreted into 
the blood stream, allows glucose to move from blood into the body cells. Normally, insulin 
attaches to its specific cell surface receptors and facilitates the transport of glucose into cells. 
This action makes insulin a requirement for the uptake of glucose from the blood stream into 
body cells, where it is metabolized and hence provides energy for cellular processes (McCance, 
2009).  
     Diabetes results from aberrations in the production or use of insulin. Excessive amounts 
of glucose in the blood stream, hyperglycemia, occurs when insulin is not sufficiently produced 
or is inefficiently utilized, preventing glucose from entering the cells and forcing it to remain in 
the blood stream. (McCance, 2009). A consequence of hyperglycemia is the irreversible bonding 
of glucose to hemoglobin in the red blood cells (RBC’s).  This process known as glycation, 
results in damage to many organs and systems of the body (McCance, 2009).   
      When blood glucose levels remain elevated, in addition to glycation of hemoglobin, other 
proteins and lipids in cellular structures also become glycated and interfere with normal cellular 
functions (McCance, 2009). In an individual with sustained elevated blood glucose levels, every 
organ and system of the body can be damaged because of the glycation process (McCance, 
2009). Long-term chronic hyperglycemia increases the risk of development of microvascular and 
macrovascular complications. Microvascular complications include, retinopathy, neuropathy, 
nephropathy, and macrovascular complications involve the cardiovascular system (American 
Diabetes Association [ADA], 2012).  Successful control of blood glucose levels can prevent and 
or delay the long-term complications associated with DM (ADA, 2011). 
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Lipids and Cardiovascular Disease 
      There are several types of lipoproteins—chylomicrons, very low-density lipoprotein 
(VLDL), low-density lipoprotein (LDL), and high-density lipoprotein (HDL)—in the human 
body that affect cardiovascular function and are measured to assess cardiovascular health. 
Lipoproteins are comprised of protein bound cholesterol, triglycerides, and phospholipids 
(McCance, 2009). Lipids have many important roles in the body. They function as components 
of plasma membranes, as hormones, and bile acids. However, abnormal levels in plasma can 
increase risk for CVD (McCance, 2009). The lipid metabolism cycle is complex, and involves 
several types of lipoproteins that are not routinely measured. For the purpose of this study, only 
the lipoproteins measured for analysis will be discussed. The low-density lipoprotein (LDL) is 
composed of mainly cholesterol and protein (McCance, 2009). While LDLs are necessary, 
higher levels promote atherogenesis thus leading to cardiovascular disease (CVD). This occurs 
with increased endothelial dysfunction and oxidation of the LDL, leading to formation of foam 
cells that get embedded in the coronary vessel wall, resulting in thickening and hardening of 
vessel walls and form plaques (McCance, 2009). The high-density lipoprotein (HDL) is 
composed of mainly phospholipids and protein (McCance, 2009).  The main role of the HDL 
component is to clear excess cholesterol from the blood stream, cell membranes, and other 
lipoproteins and return them to the liver where they form other necessary components. Low HDL 
levels have been associated with increased risk for CVD (McCance, 2009).  
      A measure of the laboratory values for LDL, HDL, and total cholesterol (TC), the sum of 
the types of cholesterol measured in blood, is used to monitor CVD in patients with diabetes 
(Buse, 2007). Normal laboratory values used as standards are; TC <200 mg/dL, LDL <100 
mg/dL, and HDL >40 mg/dL for men and >50 mg/dL for women (Buse, 2007). 
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Measures of Control and Interventions 
       Interventions provided by a qualified health care team can help delay progression and 
prevent long-term complications related to diabetes (ADA, 2011). These interventions may 
include pharmacotherapy agents, nutrition education and counseling. The health care provider 
may help manage diabetes by providing appropriate pharmacotherapy agents to help control 
glucose levels, as well as by monitoring glycemic control and treating complications that occur 
(ADA, 2011). Monitoring how well a person is controlling his/her, blood glucose is often done 
with the use of laboratory values such as the Hemoglobin A1c (HbA1c), which is a measure of 
glycated hemoglobin in the blood stream (ADA, 2012). Since the life span of RBCs is two to 
three months, glycated hemoglobin or HbA1c is an important indicator of blood glucose levels 
during an eight to twelve week period. Normal levels of HbA1c are between 4-6% (ADA, 2012).  
Since HbA1c levels are not altered by daily variations it is currently used for diagnostic purposes 
as well as a marker for overall blood glucose control (ADA, 2012). People diagnosed with 
diabetes are also evaluated regularly for serum lipid values like total cholesterol (TC), low-
density lipoprotein (LDL), and high-density lipoprotein (HDL) since they are at a higher risk for 
developing macrovascular complications (Buse, 2007).  
      Many available standards of medical care suggest that a Diabetes Self-Management 
Education program (DSMEP) is an effective intervention for helping individuals with diabetes to 
understand the disease, delay its progression and reduce associated complications (Funnell, 
2007). A qualified DSMEP uses evidence-based guidelines and is formulated to provide 
education and necessary tools to patients managing diabetes, which can ultimately reduce the 
risk of related complications (ADA, 2011). A qualified DSMEP utilizes a team of health care 
professionals such as a Registered Dietitian (RD), a Registered Nurse (RN), and often times a 
Social Worker (MSW), who are trained to provide education, skills, and support to patients with 
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diabetes. The DSMEP may be delivered on an individual or a group basis, using an evidence-
based diabetes education curriculum. Current and past research concludes that DSMEPs continue 
to remain a necessary and effective method of helping individuals control blood glucose levels 
while the patient is in contact with the DSMEP (ADA, 2011). Many programs currently exist, 
including the St. Joseph Mercy (SJM) Center for Diabetes DSMEP in Michigan. 
Saint Joseph Mercy Health System  
     The St. Joseph Mercy Health System(SJMHS) has been providing Diabetes Self-
Management Education (DSME) to patients for the past 20 years. Patients diagnosed with 
diabetes are referred to the SJM Center for Diabetes from their endocrinologist or their primary 
care physician using the SJM Center for Diabetes Service Request Form (Appendix 3). The SJM 
Center for Diabetes DSMEP is an accredited program by Michigan Department of Community 
Health and American Association of Diabetes Educators, and consists of an initial 30-minute 
evaluation by either a Registered Dietitian (RD) or a Registered Nurse (RN). If the patient has 
T1DM or T2DM and is on an exogenous insulin regimen, the initial individual visit is scheduled 
for 30 minutes with an RN and an additional 30 minutes with an RD or RN. Following the initial 
visit, the patient is scheduled for nine hours of group education in a classroom format, in the 
form of three 3-hour classes one week apart. Information is provided via live lecture and through 
supplemental books written by the SJM Center for Diabetes staff. Various topics are included 
during the course of nine hours including: diabetes overview, meal planning, medications, 
hypoglycemia, monitoring, exercise, hyperglycemia, sick day management, complications, foot 
care, community resources, dining out, label reading, chronic disease prevention, and goal 
setting.   
      Upon completion of the nine hours of classroom instruction, an hour-long individual 
follow-up visit is planned, three to six weeks subsequent to the classroom instruction. The 
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follow-up visit consists of 30 minutes with an RD and 30 minutes with an RN (Appendix 4). If 
the follow-up visit is not attended, the program is considered not completed, even if the group 
education classes were attended. The duration of the full program is approximately two to three 
months and typically no further follow-up visits are scheduled.  
      Statistics are collected on each patient at the beginning and conclusion of the program. 
Data collected for this program have continually supported favorable outcomes on HbA1c levels 
and have led to the conclusion that the SJM Center for Diabetes DSMEP is effective at lowering 
HbA1c levels in patients during attendance in the program (Karolle, 2011). To date, data have 
been lacking to support any inference that the DSMEP continues to remain effective after the 
patient is discharged from the program.  
Purpose of the Study 
      The purpose of this study is to investigate the long-term effectiveness of the SJM Center 
for Diabetes DSMEP. Current data provided by SJM Center for Diabetes states that the DSMEP 
is effective at lowering HbA1c levels from the time the patient enters into the program to the 
time the patient has received education and is discharged from the program (Karolle, 2011). This 
study will investigate the significance of changes found in HbA1c levels in the one and two years 
following the education program. This study will also investigate the significance of changes 
found in lipid values in the one and two years following the education program.  
Research Questions 
1) Is the SJM Center for Diabetes DSMEP effective at lowering and/or maintaining lowered 
HbA1c levels at one year and two years after receiving education? 
2) Is the SJM Center for Diabetes DSMEP effective at lowering and/or maintaining lowered 
lipid levels at one year and two years after receiving education? 
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Justification and Significance 
      It is has been shown that DSMEPs are an important component of patient care for people 
with diabetes (ADA, 2011). These services have been shown to help reduce the microvascular 
and macrovascular complications related to diabetes, thus leading to a decrease in hospital stays 
and the financial burden on health care systems (Funnell, 2007). Lack of DSME services can 
result in an overall increase in complications that may otherwise have been prevented (Funnell, 
2007). This study will observe long-term data on glycemic and lipid control after patients 
complete the SJM Center for Diabetes DSMEP. 
      The results from this study may be used to justify the significance of the DSMEP as an 
effective method of improving health outcomes in patients with diabetes to local physicians and 
physician groups that are converting to the Patient Centered Medical Home (PCMH) model 
(Bojadzievski & Gabbay, 2011). The PCMH model follows the Chronic Care Model, “a widely 
accepted evidence-based guide to quality improvement efforts in the primary care setting” 
(Bojadzievski & Gabbay, 2011), the goal of which is to provide the patient with a complete and 
comprehensive health care team within the same facility as the primary care physician 
(Bojadzievski & Gabbay, 2011).  
      Patient centered medical home offices generally provide any necessary health education 
within the primary care setting, often by a Nurse Practitioner  (NP; Bojadzievski & Gabbay, 
2011). If the results of this study show that the SJM Center for Diabetes DSMEP is effective at 
lowering and/or maintaining lower HbA1c levels well after the patient completes the program, it 
may justify a referral outside of the PCP office.  The SJM Center for Diabetes DSMEP may be 
viewed as a helpful adjunct to the education that is done in the primary care setting as a method 
of maintaining HbA1c levels in their patients over many years.  
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      Individuals that attend the SJM Center for Diabetes DSMEP remain in contact with 
clinicians for approximately two to three months. After the education is complete, no further 
follow-ups are planned. If the results from this study show that HbA1c levels rise significantly in 
the one to two year timeframe after the education, then this may provide the rationale needed to 
offer multiple follow-ups in the years following the education sessions.  
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Chapter 2: Review of the Literature 
Diabetes Defined 
            Diabetes is a disease of the endocrine system and can be described as a disorder of 
metabolism (McCance, 2009). There are various types of diabetes, characterized by the point of 
failure in the production or utilization of insulin. Type 1 diabetes (T1DM) is a result of the 
destruction of the beta-cells, the cells that actively produce insulin in the pancreas, which leads 
to a complete deficiency of endogenous insulin resulting in required exogenous insulin (ADA, 
2012). Type 2 diabetes (T2DM) is a progressive decline in the insulin production by the beta 
cells, where insulin production decreases over time and/or the cells of the body develop a 
resistance to the endogenous insulin produced (ADA, 2012). Gestational diabetes (GDM) is the 
diagnosis of diabetes during pregnancy (ADA, 2012).  
Diagnostic Criteria 
      The diagnostic standards for T2DM have changed over the last several years. Until 2009, 
the method for diagnosis used only: fasting plasma glucose (FPG), a non-fed state of at least 8 
hours; multiple random glucose tests, a finger stick glucose test at any time during the pre- or 
post-prandial state; or the oral glucose tolerance test (OGTT), a medical test that determines how 
quickly an oral glucose load clears the blood (ADA, 2012). In 2009 it became a diagnostic 
standard to use the Hemoglobin A1c (HbA1c) value as a method for identifying T2DM (ADA, 
2011). The HbA1c, a measure of the glucose that has irreversibly attached to the red blood cell 
or hemoglobin, known as glycosylated hemoglobin, is a laboratory value obtained from a 
venipuncture blood sample that assesses the average glucose level from the preceding two to 
three months (McCance, 2009; ADA, 2012). Once glucose attaches itself to the red blood cell, it 
remains attached until the death of that cell, which is approximately two to three months 
(McCance, 2009). The HbA1c measurement indicates the degree of glycosylated hemoglobin 
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cells currently in the blood stream, and can be converted to an average of blood glucose from the 
previous two to three months (McCance, 2009).   
      The American Diabetes Association has several criteria for diagnosing T2DM. A 
diagnosis can be made with any of the following conditions: 
 HbA1c ≥6.5%, an HbA1c within normal limits is between 4-6% (ADA, 2012). 
 FPG ≥126 mg/dl (7.0 mmol/l), a FPG within normal limits is less than 100mg/dl (ADA, 
2012). 
 2-h plasma glucose ≥200 mg/dl (11.1 mmol/l) during an OGTT. A random glucose level 
within normal limits is less than 140 mg/dl (ADA, 2012). 
 In a patient exhibiting symptoms of hyperglycemia or a random plasma glucose ≥200 
mg/dl (11.1 mmol/l) on two separate occasions. A random glucose level within normal 
limits is less than 140 mg/dl (ADA, 2012). 
Chronic Complications of Diabetes 
      Diabetes is a disease that affects every system of the body and can result in various 
chronic microvascular and macrovascular complications (McCance, 2009). The microvascular 
complications include neuropathy, nephropathy, and retinopathy (McCance, 2009). 
Macrovascular diseases include peripheral vascular disease, stroke, and cardiovascular disease 
(CVD) (1).  
      Several long-term studies completed to date measure the implications of glycemic control 
on CVD. The Diabetes Control and Complications Trial (DCCT) followed 1441 individuals with 
T1DM from 1983-1993 (Nathan et al., 2005). Ninety-three percent of the individuals continued 
in the follow-up study, the Epidemiology of Diabetes Interventions and Complications (EDIC) 
until 2005. The DCCT/EDIC study occurred over 20 years, with a mean follow-up of 17 years. 
The goal of both studies was to obtain a mean HbA1c level of 6.05%. However, the mean 
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HbA1c obtained at the end of the DCCT was 7.4%, and at the end of the EDIC study was 7.9% 
for the intensive therapy group (Nathan et al., 2005). At the end of the EDIC study, the intensive 
therapy group was associated with a 42% reduction in cardiovascular events, when compared 
with the conventional therapy group, which had a mean HbA1c of 9.1% at the end of the DCCT, 
and 7.8% at the end of the EDIC study (Nathan et al., 2005). 
      The original United Kingdom Prospective Diabetes Study (UKPDS) study reported that 
T2DM patients who received intensive glucose lowering therapy (insulin, sulfonylurea, or 
metformin) and reached a mean HbA1c of 7.0% were able to improve their microvascular 
outcomes by 25% over the conventional group, which had a mean HbA1c of 7.9% (UK 
Prospective Diabetes Study [UKPDS], 1999). Despite the significant reductions in HbA1c 
values, there were no improvements in macrovascular outcomes (UKPDS, 1999). In addition, 
there appeared to be no better glycemic control regardless of the therapy used in the intensive 
group, so the principal factor for microvascular risk reduction lies in general improvement of 
glycemic control (UKPDS, 1999).      
      During the 10-year long-term follow up study to the UKPDS, no further interventions 
occurred; however, the benefits of the original therapy continued for several years after the 
original intervention (Holman, Paul, Bethel, Matthews & Neil, 2008). The follow-up results 
support the original findings of reported reductions in microvascular complications (Holman et 
al., 2008). Only in the long-term follow-up did reductions in macrovascular complications 
emerge. At this time, differences were found within the intensive therapy groups regarding 
macrovascular complications. In the sulfonylurea-insulin group, there was a 15% reduction in 
myocardial infarction, and a 13% decrease in death secondary to any cause compared to the 
control group (Holman et al., 2008). The metformin group showed a 39% reduction in 
myocardial infarctions and a 36% decrease in death from any cause (Holman et al., 2008). Both 
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groups showed similar reductions in microvascular complications. This latent outcome on 
macrovascular risk has been called the legacy effect, suggesting that the benefits take a longer 
time to accrue and emerge (Holman et al., 2008). The legacy effect points to the need for 
continued long-term support and management in patients with T2DM to help maintain lowered 
glycemic and lipid levels for optimal risk reduction (Holman et al., 2008).  
      In the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified 
Release Controlled Evaluation (ADVANCE) trial, the results were similar to the UKPDS 
(ADVANCE Collaborative Group [ADVANCE], 2008). The ADVANCE trial had a greater 
emphasis on lifestyle management in addition to the pharmacological agents studied in the trial. 
Microvascular reductions were significant at 14% in the intensive therapy group when compared 
to the standard therapy group (ADVANCE, 2008). Comparable to UKPDS, there was an 
insignificant decrease in macrovascular events of 6% over the 5-year study period (ADVANCE, 
2008). The ADVANCE-ON study is the long-term study currently in progress and expected to 
continue collecting data until the end of 2013 looking at the continuing implications of the 
ADVANCE trial (Hamet, 2012). It is anticipated that similar results to the UKPDS 10-year 
follow-up will appear in macrovascular results, which will further support the legacy effect of 
optimal glycemic control on macrovascular risk (Hamet, 2012).  
      The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial failed to assess 
whether achieving a target HbA1c level of 6.0% would significantly reduce cardiovascular risk 
and complications in individuals with T2DM (ACCORD Study Group [ACCORD], 2011). The 
intensive therapy group of the study was terminated prior to completion because of a high 
incidence of mortality within the intensive group (ACCORD, 2014). The participants of the 
ACCORD trial were at a high risk for CVD and were on average older than previous studies 
(DCCT/EDIC, UKPDS, ADVANCE; ACCORD, 2014). The cause of the higher rate of mortality 
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in the ACCORD trial is unknown; however, hypoglycemic events were ruled out as the principal 
factor (ACCORD, 2014). The failure in the ACCORD study suggests that the intensive treatment 
approach may be an unsuitable treatment option for a high-risk, older population. 
      Another short-term trial that failed to reproduce the reduction in microvascular and 
macrovascular risk found in the DCCT and UKPDS was the Veterans Affairs Diabetes Trial 
(VADT; Duckworth et al., 2009). This trial was completed on veterans, predominately men, who 
had the diagnosis of T2DM for an average of 11.5 years with uncontrolled glucose levels 
(Duckworth et al., 2009). The mean HbA1c at the study’s inception was 9.4%. Many of the 
individuals had already experienced a cardiovascular event; the exclusion was that they did not 
have an event that had occured in the past 6 months. The participants in this study were at a 
higher risk for complications related to the length of diagnosis, present complications, as well as 
the inadequate response to maximum doses of oral agents or insulin (Duckworth et al., 2009). 
The mean HbA1c levels at the end of the study were 8.4% for the standard therapy and 6.9% for 
the intensive therapy (Duckworth et al., 2009). All individuals received the same basic standard 
of care set forth by the American Diabetes Association (ADA), including education, dietary 
information, and follow-up. The intensive therapy group received more aggressive oral anti-
diabetic agents and/or insulin. Even with the reduction in HbA1c levels for the intensive group, 
there were no significant differences in the rates of microvascular complications, macrovascular 
complications, or death from any cause (Duckworth et al., 2009).  
      These studies propose that complications are more difficult to control and prevent in the 
patient with T2DM, and more challenging in the uncontrolled, high-risk group. Controlled 
glycemic levels alone are not enough among individuals with T2DM, especially the high-risk 
group; there is a need for appropriate management of dyslipidemia and other cardiovascular risk 
14 
 
factors. As a result, the incorporation of related complication risk reduction and management has 
become a part of many DSME programs (ADA, 2011).  
Standards of Care 
      Diabetes is a chronic condition that can result in multiple acute and long-term 
complications (ADA, 2011). This chronic disease requires complex continuing medical care as 
well as self-management, education, and support to help reduce and/or delay the onset of 
diabetes related complications (ADA, 2011). The Standards of Medical Care in Diabetes have 
been implemented as a guide for managing the multifaceted care required for the individual with 
diabetes (ADA, 2011). These standards include recommendations for health care providers for 
screening, diagnosing, and care planning, which have been known to provide a positive outcome 
in the health of the patient with diabetes (ADA, 2011). 
      Diabetes care should provide a complete and comprehensive plan including, but not 
limited to: ongoing evaluations, physical assessments/examinations, and laboratory evaluations 
(ADA, 2011). Referrals should be made for annual dilated eye examinations, dental 
examinations, family planning, Medical Nutrition Therapy (MNT), Diabetes Self-Management 
Education (DSME), and mental health professionals as needed. The DSME program is an 
essential piece of the comprehensive care plan and follows the national standards and evidence-
based practices in providing education, skill building, and support to people with diabetes (ADA, 
2011).   
      This is a cost-effective method that empowers patients to take an active role in their self-
care, which can improve health outcomes overall; however, the research and data on the long-
term effectiveness of the DSME on health outcomes remains lacking (ADA, 2011). This study 
will help to provide some longer-term data about the effectiveness of the SJM Center for 
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Diabetes DSME program, which is based on the American Association of Diabetes Educators 
standards that accredit DSME programs (Funnell, 2007). 
Diabetes Self-Management Education Programming 
      Because of the diverse nature of the United States population, it is relevant to look at 
some of the DSMEPs that have proven to be successful in other countries. While the structure of 
a DSMEP may vary, the goal is to reduce HbA1c levels and ultimately reduce the complications 
related to T2DM (ADA, 2011). One of the variables in DSMEP structure is the span of time that 
the patients are in the program. The Joetsu Diabetes Prevention Trial from Joetsu, Japan, is a 
study that looked at the difference in outcomes between a 2-day hospital stay program and a 
longer-term outpatient program, when compared to a control group that received no education 
(Kawahara et al., 2008). It was found that the direct and intensive contact of the 2-day hospital 
stay was very effective at lowering the risk for developing or delaying the progression of T2DM 
(Kawahara et al., 2008). It proved to be more effective than the longer term outpatient program, 
which was far more effective than providing no education at all (Kawahara et al., 2008). The cost 
effectiveness did not appear to be an issue, based on the health care system in Japan (Kawahara 
et al., 2008). However, a two-day hospital stay in the U.S. would be entirely cost prohibitive 
under the current health care system here.  
      The majority of diabetes education in Japan is provided in the hospital setting and as a 
result, there are fewer outpatient clinics that provide complete DSME (Adachi et al., 2010). 
Another on-going study in Japan is investigation the effectiveness of providing more complete 
DSME by a Registered Dietitian in the general practitioners (GP) medical clinic, which follows 
similar guidelines and standards as the U.S. national DSME standards (Adachi et al., 2010). The 
control group received general nutrition guidelines within the medical practice, similar to what 
would be provided by the GP (Adachi et al., 2010). It is important to note that this is one of the 
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first cluster randomization studies to be done in Japan, and it is expected that the results from this 
study will provide favorable health outcomes (Adachi et al., 2010).  
      More studies from around the world are reporting that the modification of lifestyle is an 
integral piece in reducing risks related to diabetes. A study from Finland and Australia is looking 
at the mode of delivery of diabetes education (Oldenburg, Absetz, Dunbar, Reddy & O’Neil, 
2011). There are varying barriers to success in individuals around the world. This study looked at 
programs over the past 10 years and identified that the use of a variety of methods of delivering 
education are necessary in reaching high-risk individuals with diabetes (Oldenburg et al., 2011). 
A significant determinant of success for these programs is the governmental support for the 
resource-poor settings (Oldenburg et al., 2011).   
      Active Steps for Diabetes is a program in the US that has incorporated physical activity 
into their DSME (Pariser, Demeuro, Gillette & Stephen, 2010). It has been well known that 
physical activity is a modifiable lifestyle component that can have a greater impact on the 
development and progression of diabetes (ADA, 2011). The challenge for many DSME 
programs is the differing physical capabilities and mobility issues of each patient within the 
group (Pariser et al., 2010). This program has successfully integrated the physical activity 
component and has shown some positive results in improving health outcomes and reducing the 
comorbidities related to diabetes including coronary artery disease as well as increasing overall 
mobility in patients with such difficulties (Pariser et al., 2010).  
      One study completed in the UK examined the effects of education on individuals with 
newly diagnosed T2DM using a three-year follow up after initial diagnosis and intervention 
(Khunti et al., 2012). The control group did not receive any nutrition education although patients 
received regular care by the general practice physician while the individuals in the intervention 
group completed a DSME shortly after they were diagnosed with T2DM (Khunti et al., 2012). 
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The results at the 3-year follow up reported no significant change in laboratory values, including 
HbA1c, or health outcomes between the control and intervention group (Khunti et al., 2012).  
      However, when looking at the long- term follow up study of the Diabetes Prevention 
Program (DPP) known as the Diabetes Prevention Program Outcomes Study (DPPOS), these 
results clearly state that lifestyle interventions have a positive impact on the reduction of risk 
factors that lead to the diagnosis to T2DM (Diabetes Prevention Program Research Group [DPP], 
2009). The DPPOS followed individuals who completed the DPP, and reported that the effects of 
lifestyle intervention can delay diabetes for up to 10 years (DPP, 2009). In addition to the 
lifestyle intervention, one arm of the study looked at metformin use as a means to delay 
development of T2DM. The total incidence of diabetes in the lifestyle group was less than the 
incidence of diabetes in the metformin group (DPP, 2009). It is important to note that both 
groups were instrumental in delaying the diagnosis of diabetes, but the lifestyle group appeared 
to have a greater impact over a longer period of time (DPP, 2009). Because of this large, long-
term study, the lifestyle interventions and DSME programs deserve an in-depth look in delaying 
the progression of diabetes, and the reduction of diabetes related complications after diagnosis.  
      The primary care provider’s office is an increasingly popular delivery site for diabetes 
education (Whittemore et al., 2010).  Nurse Practitioners (NP) are employed more often to 
provide education not only for diabetes, but for many chronic illnesses, within the primary care 
office (Whittemore et al., 2010). The results of a pilot study reviewing the delivery of diabetes 
education by the NP has shown that it can be successful in eliciting behavior change; however, 
more evidence is needed to determine the effects on lowering HbA1c and lipid levels 
(Whittemore et al., 2010). A qualitative study reviewed some of the reasons that general 
practitioners (GP) hesitate to refer patients to an outside DSME program (Sunaert et al., 2011). 
The general consensus is that GPs needed time to understand the role of the DSME, and develop 
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a trusting relationship between the groups and understand that their patients care would not be 
compromised or fragmented by deferring the education to the DSME (Sunaert et al., 2011). 
Stand-alone diabetes education programs may need to reinforce their effectiveness and provide 
more long term efficacy data as there is a shift to providing more diabetes education within the 
primary care setting. 
           While proving the effectiveness of a DSME is necessary to comply with the evidence-
based culture of the U.S. health care system, it is also necessary to show that it is a cost-effective 
strategy in producing favorable outcomes. One study delineated the top cost-effective 
interventions for people with T2DM (Li, Zhang, P, Barker, Chowdjury & Zhang, X, 2010). The 
most cost effective intervention was primary prevention and the use of intensive lifestyle 
modifications to prevent and delay the diagnosis of T2DM (Li et al., 2010). There was strong 
evidence supporting the cost-effectiveness of programs like the DPP, and intensive lifestyle 
interventions for people with newly diagnosed T2DM in maintaining glycemic control (Li et al., 
2010). Finally, the DSME proved to be very cost-effective at maintaining glycemic control when 
compared with individuals who received no diabetes education (Li et al., 2010).  
      Hospitals and emergency departments stand to see the greatest cost reduction through the 
use of DSME (Dall et al., 2011). The agency that administers health care benefits for military 
personnel known as TRICARE has shown that the greatest burden of cost by diabetes patients is 
from recurring inpatient hospital stays and emergency room visits by individuals with 
uncontrolled T2DM who have not participated in any DSME (Dall et al., 2011). Individuals who 
were reported to have uncontrolled T2DM and participated in TRICARE’s, DSME realized 
better health outcomes, and were associated with lowered medical costs overall (Dall et al., 
2011). 
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      The available literature accurately describes the multifaceted nature of diabetes and the 
complications that can arise. These complexities increase as the individual ages, or develop 
uncontrolled glucose levels. The DSMEP must be able to meet the complicated needs of the 
diabetes population. It is now more evident that the DSMEP must address the cardiovascular risk 
factors as well as optimal glucose control of the individual. Multiple studies support the efficacy 
and cost-effectiveness of the DSMEP in managing diabetes care. This study will provide longer-
term data to support the efficacy of the SJM Center for Diabetes DSMEP in lowering the risks of 
complications related to diabetes in a cost-effectiveness manner. 
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Chapter 3: Research Design and Methodology 
      The primary objective of this study was to determine if the SJM Center for Diabetes 
DSMEP is effective in lowering or maintaining lowered HbA1c and lipid levels at the one and 
two-year mark following the education program. This was a quantitative study using existing 
patient data collected in 2010, 2011, and 2012.  
Study Population 
      The population of this study included patients enrolled in the SJM Center for Diabetes 
DSMEP in 2010, including all adult (age 18 and older) patients diagnosed with Type 2 Diabetes. 
The mean age of the study participants was 64 years. Study participant exclusions included 
participants diagnosed with gestational diabetes, participants diagnosed with Type 1 Diabetes, 
participants diagnosed with pre-diabetes, participants that did not complete the diabetes 
education group classes (nine-hours of classroom education), participants that enrolled in the 
SJM NutriCare (weight management) program, and participants that died during the data 
collection period. 
Ethical Considerations 
      No live subjects were used in this study. Data were extracted from the SJMH electronic 
medical record using the participant’s SJMH Medical Record Number (MRN) only. The SJMH 
MRN# was decoded to protect the names and information of the individuals included in the 
study. No other personal information was used at any time for the duration of this study.  All data 
collected were kept in a locked cabinet in the locked office of the principal investigator. All 
electronic data were stored in a password-protected file on the computer of the principal 
investigator. The principal investigator will destroy all identifiable data at the conclusion of this 
study. This protocol was approved by the College of Health and Human Services, Human 
subjects Review Committee, Eastern Michigan University, Ypsilanti, MI (see Appendix 2).  
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Data Collection 
      The SJM Center for Diabetes stores participant records in a protected Microsoft Access 
database. A report query from this database captured all of the patients who participated in 
diabetes education classes in 2010. The study population was gathered from the report query, 
exercising the appropriate exclusions. The remaining patients became the study participants.  
      SJMH uses PowerChart™, an electronic medical record that contains the full medical 
record of all patients within the SJMH system, including laboratory data collected at any SJMH 
site. Each study participant had information recorded from PowerChart™ at the following data 
collection points: Baseline, Post-Program, 1-year Post-Program, and 2-years Post-Program. The 
laboratory values recorded were: HbA1c, LDL cholesterol, HDL cholesterol, and TC. The 
Baseline and Post-Program HbA1c values were recorded to verify the initial change in HbA1c 
levels after completing the group education sessions. Lipid values were recorded for the same 
Baseline and Post-Program period if available in PowerChart™. The data collected 1-year Post-
Program and 2-year Post-Program were used to investigate any further changes in HbA1c, and 
lipid values. The data were recorded on an excel spreadsheet for each participant. 
Data Analysis 
      The data collected for each individual in the categories, HbA1c, LDL, HDL, and TC were 
evaluated at baseline, Post-Program, 1-year Post-Program, and 2-years Post-Program. Data 
analysis was performed using IBM SPSS Statistics 21 software (IBM SPSS Statistics 21.0, 2012, 
IBM Corporation, Somers, NY) with the assistance of the College of Health and Human Services 
(CHHS) Inter-Professional Research Office (iPRO). The repeated measures analysis of variance 
(ANOVA) and sample t-tests were used, with a 95% Confidence Interval,  p<.05, to determine 
the level of significance in changes from baseline, post-program, 1-year post-program, and 2-
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years post-program, then compared to the target ranges recommended by the standards of care 
for changes for each category in patients that have T2DM.  
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Chapter 4: Research Results 
Demographics 
      During the year 2010, 299 individuals took part in the SJM Center for Diabetes DSMEP. 
Of the 299 that took part in the education program, data for 234 individuals was extracted from 
PowerChart™, the SJMH electronic medical record; 64 individuals did not have laboratory data 
available and were excluded from the final sample population. One individual died during the 
study period and was excluded from the sample. The demographical characteristics of the study 
population (n=234) are: female (n=135) and male (n=99) participants ages 18-99, with a mean 
age of 64. No distinctions were made for age or race.   
HbA1c Values 
     Demographic characteristics are presented in Table 1. There were 131 individuals with 
HbA1c values available for all data collection points. Of the 131 individuals, 81 (62%) were 
females and 50 (38%) were males. Program completion determined by attendance at follow-up 
visit was 55% (n=72), and 45% (n=59) did not complete the program by not attending the 
follow-up visit, shown in Table 2.  
Table 1. Demographic characteristics 
  Total (n) % of population 
HbA1c Values Available 131 100% 
Gender 
 
  
Female 81 62 
Male 50 38 
      
      Table 2 presents the HbA1c percent mean values for each data collection point by gender, 
program completion for both genders, and for all groups. Data were evaluated to see if there 
were any significant differences in HbA1c percent whether the program was completed or not. 
Every study participant attended the nine-hour education classes. The program was considered 
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completed if the individual attended the one-hour individual visit following the nine hours of 
education classes, 30 minutes with an RD, and 30 minutes with an RN. Table 2 also provides a 
comparison of HbA1c levels from Baseline to Post-Program, Post Program to1-year Post-
Program, 1-year Post-Program to 2-years Post-Program, and from Baseline to 2-years Post-
Program for gender, program completion, and all groups. Repeated measures ANOVA showed 
that there was a significant effect on HbA1c percent levels for receiving education through the 
SJM Center for Diabetes DSMEP. 
Table 2: Reported HbA1c percent values for Gender, Program Completion, and all groups at Baseline, Post-Program, 1-year Post-Program, 2-year Post-
Program; and the t-test comparison of HbA1c percent levels from Baseline to Post-Program,  Post-Program to1-year Post-Program, and 1-year Post-Program to 
2-years Post-Program, and from Baseline to 2-years Post-Program. 
 
Baseline 
HbA1c %      
Mean ± SD  
Post-
Program 
HbA1c % 
Mean ± SD  
Baseline 
to Post-
Program  
p-value 
1-year 
Post-
Program 
HbA1c % 
Mean ± SD 
Post-
Program 
to    
1-year  
p-value 
2-years 
Post-
Program 
HbA1c % 
Mean ± SD 
1-year to  
2-year  
p-value 
Baseline 
to 
2-year 
p-value 
Gender 
      
   
Females (n=81) 8.08 ± 1.82 6.70 ± 0.93 p<0.0001 6.78 ± 1.02 p=0.6025 6.87 ± 1.24 p=0.6232 p<0.0001 
Males (n=50) 8.72 ± 2.14 6.69 ± 1.08 p<0.0001 6.98 ± 1.11 p=0.2003 7.03 ± 1.33 p=0.8259 p<0.0001 
Program Completion a 
      
   
Program Completed (n=72)b 7.97 ± 1.71 6.49 ± 0.91 p<0.0001 6.64 ± 0.90 p=0.3041 6.88 ± 1.14 p=0.1794 p<0.0001 
Program Not Completed (n=59)b 8.76 ± 2.18 6.95 ± 1.02 p<0.0001 7.11 ± 1.18 p=0.4323 6.99 ± 1.43 p=0.6310 p<0.0001 
  
      
   
HbA1c% for all groups (n=131)a,b,c 8.33 ± 1.97 6.70 ± 0.98 p<0.0001 6.86 ± 1.05 p=0.2112 6.93 ± 1.28 p=0.6044 p<0.0001 
       
   
SD=Standard Deviation 
      
   
P is significant at less than .05 
a Program completed as determined by attendance at the follow-up visit.  
b Includes females and males. 
c Includes Program Completed and Not Completed. 
   
 
      The standards of medical care for people with diabetes recommend reaching and 
maintaining an HbA1c percentage of 7% or below for improved health outcomes (ADA, 2011). 
The recorded HbA1c percent values provided a mean HbA1c percent for females at Baseline of 
8.08%. From Baseline to Post-Program, there was a significant decrease of 1.38% in HbA1c 
percentage to 6.70% (p<0.0001). The HbA1c percentage for 1-year Post-Program for females 
was 6.78%, which was a very slight but insignificant increase of 0.08% (p=0.6025) from Post-
Program. The HbA1c percentage for 2-years Post-Program for females was 6.87%, which was a 
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slight but insignificant increase from 1-year Post-Program of 0.09% 9 (p=0.6232). Comparing 
the change from Baseline to 2-years Post-Program, there was a significant reduction in HbA1c 
percentage for females of 1.21% (p<0.0001). The mean HbA1c percentage for females reached 
the target level for HbA1c percentage of <7% (ADA, 2011) at the Post-Program point and 
remained on target through the 2-years Post-Program point, suggesting that the interventions 
provided by the SJM Center for Diabetes DSMEP were effective at lowering and maintaining 
lowered HbA1c levels for females through two years after the program intervention.  
      The recorded HbA1c percent values provided a mean HbA1c percent for males at 
Baseline of 8.72%. From Baseline to Post-Program, there was a significant decrease of 2.03% in 
HbA1c percentage to 6.69% (p<0.0001). The HbA1c percentage for 1-year Post-Program for 
males was 6.98%, which was a slight but insignificant increase of 0.29% (p=0.2003) from Post-
Program. The HbA1c percentage for 2-years Post-Program for males was 7.03%, which was 
slight but insignificant increase of 0.05% (p=0.8259) from 1 year Post-Program. Comparing the 
change from Baseline to 2-years Post-Program, there was a significant decrease in HbA1c 
percentage for males of 1.69% (p<0.0001). Even though the mean HbA1c percentage for males 
at the 2-years Post-Program was only slightly above the recommended target of <7% (ADA, 
2011), there was a significant improvement in HbA1c percentage for males at the 2-year Post-
Program point. 
      For the individuals that completed the program, the Baseline mean HbA1c percentage 
was 7.97%. There was a significant decrease of 1.48% from Baseline to Post-Program, which 
was 6.49% (p<0.0001). The 1-year Post-Program HbA1c percentage was 6.64%, which was an 
insignificant increase of 0.15% (p=0.3041) from Post-Program. The HbA1c percentage for  
2-years Post Program for those that completed the program was 6.88%, which was an 
insignificant increase of 0.24 (p=0.1794) from 1-year Post-Program. Comparing the change from 
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Baseline to 2-years Post-Program there was a significant decrease in HbA1c of 1.09% 
(p<0.0001), for those that completed the program by attending the follow up visit.  
      For the individuals that did not complete the program, the Baseline mean HbA1c 
percentage was 8.76%. There was a significant decrease of 1.81% from Baseline to Post-
Program, which was 6.95% (p<0.0001). The 1-year Post-Program HbA1c percentage was 7.11%, 
which was an insignificant increase of 0.16% (p=0.4323) from Post-Program. The HbA1c 
percentage for 2-years Post Program for those that did not complete the program was 6.99%, 
which was an insignificant decrease of 0.12% (p=0.6310) from 1-year Post-Program. Comparing 
the change from Baseline to 2-years Post-Program there was a significant decrease in HbA1c of 
1.77% (p<0.0001), for those that did not complete the program by not attending the follow up 
visit.  
      When combined, looking at all groups together including males, females, those that 
completed the program by attending the follow up visit and those that did not, the mean HbA1c 
percentage at Baseline was 8.33%. There was a significant decrease of 1.63% from Baseline to 
Post-Program, which was 6.70% (p<0.0001) suggesting that the initial intervention was 
successful at lowering HbA1c levels. There was an insignificant increase of 0.16% from Post-
Program to 1-year Post-Program, which was 6.86% (p=0.2112). The 2-year Post-Program mean 
HbA1c percentage for all groups was 6.93%, which was an insignificant increase of 0.07% 
(p=0.6044) from 1-year Post-Program. Comparing the change from Baseline to 2-years Post-
Program, there was a significant decrease in HbA1c percentage of 1.4% (p<0.0001). The mean 
HbA1c percentage for all groups showed significant improvement from Baseline to 2-years Post-
Program, and was below the target of 7% in the Post-Program points through 2-years Post-
Program, showing that the program interventions were successful in lowering HbA1c percentage 
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levels, as well as maintaining lowered HbA1c percentage levels for the two years following the 
education program. 
LDL Values 
      Table 3 presents the mean LDL (mg/dL) values of each data collection point by gender, 
program completion, and for all groups. There were 112 individuals with LDL values collected 
(n=112). Of those 112, 63 (46%) were female and 49 (44%) were male. Table 3 also provides a 
comparison of LDL (mg/dL) levels from Baseline to Post-Program, Post-Program to1-year Post-
Program, 1-year Post-Program to 2-years Post-Program, and Baseline to 2-years Post-Program 
for gender, program completion, and all groups. Repeated measures ANOVA show that there 
was a significant effect on improving LDL (mg/dL) levels from receiving education through the 
SJMH Center for Diabetes DSMEP. 
Table 3: Reported LDL(mg/dL) values for Gender, Program Completion, and all groups at Baseline, Post-Program, 1-year Post-Program, 2-year Post-Program; 
and the t-test comparison of LDL (mg/dL) levels from Baseline to Post-Program,  Post-Program to 1-year Post-Program, 1-year Post-Program to 2-years Post-
Program, and Baseline to 2-years Post-Program. 
 
Baseline 
LDL (mg/dL)      
Mean ± SD 
Post-
Program 
LDL (mg/dL)      
Mean ± SD 
Baseline to 
Post-
Program  
p-value 
1-year Post-
Program  
LDL (mg/dL)      
Mean ± SD 
Post-
Program to 
1-year  
p-value 
2-years Post-
Program  
LDL (mg/dL)      
Mean ± SD 
1-year to  
2-year  
p-value 
Baseline to  
2-year 
p-value 
Gender         
Females (n=63)  114.2 ± 35.2 98.4 ± 29.9 p=0.0076 92.4 ± 26.8 p=0.2379 90.0 ± 28.5 p=0.6272 p<.0001 
Males (n=49) 110.4 ± 35.7 95.6 ± 31.3 p=0.0315 90.5 ± 31.3 p=0.4219 92.7 ± 39.8 p=0.7617 p=0.0226 
Program Completion a         
Program Completed (n=62)b 112.1 ± 33.4 98.3 ± 31.4 p=0.0193 87.9 ± 28.1 p=0.0543 88.4 ± 36.2 p=0.9317 p=0.0002 
Program Not Completed (n=50)b 113.2 ± 37.9 95.8 ± 29.4 p=0.0118 96.1 ± 29.1 p=0.9592 94.6 ± 30.5 p=0.8019 p=0.0081 
         
LDL (mg/dL) for all groups 
(n=112)a,b,c 
112.5 ± 35.4 97.2 ± 30.4 p=0.0006 91.6 ± 28.7 p=0.1577 91.2 ± 33.8 p=0.9240 p<0.0001 
         
SD=Standard Deviation         
P is significant at less than .05 
a Program completed as determined by attendance at the follow-up visit.  
b Includes females and males. 
c Includes Program Completed and Not Completed. 
  
 
     The target LDL (mg/dL) for people with diabetes is <100 mg/dL (Buse et al., 2007). The 
recorded LDL (mg/dL) values provided a mean LDL (mg/dL) for females at Baseline of 114.2 
mg/dL. The Post-Program mean LDL was 98.4 mg/dL, which was a significant decrease of 15.8 
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mg/dL from Baseline (p=0.0076). The 1-year Post-Program LDL (mg/dL) was 92.4 mg/dL, 
which was an insignificant decrease of 6 mg/dL (p=0.2379) from Post-Program. The 2-year Post-
Program LDL (mg/dL) for females was 90.0 mg/dL, which was an insignificant decrease of 2.4 
mg/dL (p=0.6272) from 1-year Post-Program. Comparing the Baseline and 2-years Post-Program 
LDL (mg/dL) for females, there was a significant decrease of 24.2 mg/dL (p<0.0001). LDL 
(mg/dL) levels continued to improve through each collection point. Females reached the target 
LDL (mg/dL) range in the Post-Program point and remained below the target range through the 
2-years Post-Program point, suggesting that the SJM Center for Diabetes DSMEP was effective 
in lowering and maintaining lowered LDL (mg/dL) levels for females.  
      The recorded LDL (mg/dL) values provided a mean LDL (mg/dL) for males at Baseline 
of 110.4 mg/dL. The Post-Program mean LDL was 95.6 mg/dL, which was a significant decrease 
of 14.8 mg/dL from Baseline (p=0.0315). The 1-year Post-Program LDL (mg/dL) was 90.5 
mg/dL, which was an insignificant decrease of 5.1 mg/dL (p=0.4219) from Post-Program. The 2-
year Post-Program LDL (mg/dL) for males was 92.7 mg/dL, which was an insignificant increase 
of 2.2 mg/dL (p=0.7617) from 1-year Post-Program. Comparing the Baseline and 2-years Post-
Program LDL (mg/dL) for males, there was a significant decrease of 17.7 mg/dL (p=0.0226). 
LDL (mg/dL) levels improved from Baseline through 1-year Post-Program and then showed an 
increase at 2 years Post-Program. Even though the LDL (mg/dL) levels increased very slightly at 
the 2-year Post-Program point, males reached the target LDL (mg/dL) range in the Post-Program 
point and remained below the target range through the 2-years Post-Program, again supporting 
the initial effectiveness of the SJM Center for Diabetes DSMEP.  
           For the individuals that completed the program, the Baseline mean LDL (mg/dL) was 
112.1 mg/dL. There was a significant decrease of 13.8 mg/dL from Baseline to Post-Program, 
which was 98.3 mg/dL (p=0.0193). The 1-year Post-Program LDL (mg/dL) was 87.9 mg/dL, 
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which was an insignificant decrease of 10.4 mg/dL (p=0.0543) from Post-Program. The LDL 
(mg/dL) for 2-years Post Program for those that completed the program was 88.4 mg/dL, which 
was an insignificant increase of 0.5 mg/dL (p=0.9317) from 1-year Post-Program. Comparing the 
change from Baseline to 2-years Post-Program there was a significant decrease in LDL (mg/dL) 
of 23.7 mg/dL (p=0.0002), for those that completed the program by attending the follow up visit, 
and all Post-Program points were below the target range. 
   For the individuals that did not complete the program, the Baseline mean LDL (mg/dL) 
was 113.2 mg/dL. There was a significant decrease of 17.4 mg/dL from Baseline to Post-
Program, which was 95.8 mg/dL (p=0.0118). The 1-year Post-Program LDL (mg/dL) was 96.1 
mg/dL, which was an insignificant increase of 0.3 mg/dL (p=0.9592) from Post-Program. The 
LDL (mg/dL) for 2-years Post Program for those that did not complete the program was 94.6 
mg/dL, which was an insignificant decrease of 1.5 mg/dL (p=0.8019) from 1-year Post-Program. 
Comparing the change from Baseline to 2-years Post-Program there was a significant decrease in 
LDL (mg/dL) of 18.6 mg/dL (p=0.0081), for those that did not complete the program by 
attending the follow up visit, and all Post-Program points were again below the target range for 
LDL (mg/dL).  
           Comparing all groups together, both genders, those that completed the program by 
attending the follow up visit and those that did not, the mean LDL (mg/dL) at Baseline was 
112.5 mg/dL. There was a significant decrease of 15.3 mg/dL from Baseline to Post-Program, 
which was 97.2 mg/dL (p=0.0006). There was an insignificant decrease of 5.6 mg/dL (p=0.1577) 
from Post-Program to 1-year Post-Program, which was 91.6 mg/dL. The 2-year Post-Program 
mean LDL (mg/dL) for all groups was 91.2 mg/dL, which was an insignificant decrease of 0.4 
mg/dL (p=0.9240) from 1-year Post-Program. Comparing the change from Baseline to 2-years 
Post-Program, there was a significant reduction in LDL (mg/dL) of 21.3 mg/dL (p<0.0001). The 
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mean LDL (mg/dL) for all groups was below the target of 100 mg/dL in all of the Post-Program 
points through 2-years Post-Program, again showing the success of the interventions provided in 
the SJM Center for Diabetes DSMEP. 
HDL Values 
      Table 4 presents the mean HDL values at each data collection point for gender and a 
comparison of mean HDL levels for gender between each of the data collection points. HDL 
values were available for 117 individuals (n=117) for all data collection points. Of the 117 
individuals, n= 63 (54%) were female and n= 54 (46%) were male. Table 4 also provides a 
comparison of HDL (mg/dL) levels from Baseline to Post-Program, Post-Program to1-year Post-
Program, 1-year Post-Program to 2-years Post-Program, and Baseline to 2-years Post-Program 
for gender, program completion, and all groups.  Repeated measures ANOVA showed that there 
was a significant effect on HDL levels after receiving education through the SJMH Center for 
Diabetes DSMEP. 
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Table 4: Reported HDL (mg/dL) values for Gender, Program Completion, and all groups at Baseline, Post-Program, 1-year Post-Program, 2-year Post-Program; 
and the t-test  comparison of HDL (mg/dL) levels from Baseline to Post-Program,  Post-Program to1-year Post-Program, 1-year Post-Program to 2-years Post-
Program, and Baseline to 2-years Post-Program. 
 
Baseline 
HDL (mg/dL)      
Mean ± SD 
Post-
Program 
HDL (mg/dL)      
Mean ± SD 
Baseline to 
Post-
Program  
p-value 
1-year Post-
Program  
HDL (mg/dL)      
Mean ± SD 
Post-
Program to 
1-year  
p-value 
2-years Post-
Program  
HDL (mg/dL)      
Mean ± SD 
1-year to  
2-year  
p-value 
Baseline to  
2-year  
p-value 
Gender         
Females (n=63)  46.7 ± 13.7 49.2 ± 12.2 p=0.2815 51.3 ± 13.2 p=0.3556 52.8 ± 11.9 p=0.5042 p=0.0086 
Males (n=54) 37.7 ± 8.5 40.0 ± 9.2 p=0.1801 44.4 ± 13.0 p=0.0448 45.0 ± 12.3 p=0.8059 p=0.0005 
Program Completion a         
Program Completed (n=64)b 43.6 ± 14.3 45.6 ± 13.4 p=0.4158 49.3 ± 15.0 p=0.1436 50.2 ± 14.2 p=0.7280 p=0.0099 
Program Not Completed (n=53)b 41.2 ± 9.6 44.3 ± 9.6 p=0.0995 46.7 ± 11.4 p=0.2437 48 ± 10.7 p=0.5463 p=0.0008 
         
HDL (mg/dL) for all 
groups(n=117)a, b, c 
42.5 ± 12.4 45.0 ± 11.8 p=0.1155 48.1 ± 13.5 p=0.0627 49.2 ± 12.7 p=0.5215 p<0.0001 
         
SD=Standard Deviation         
P is significant at less than .05 
a Program completed as determined by attendance at the follow-up visit.  
b Includes females and males. 
c Includes Program Completed and Not Completed. 
  
      
      The target recommended HDL (mg/dL) for females with diabetes is >50 mg/dL (Buse et 
al., 2007). The goal for HDL (mg/dL) levels is to increase and remain above the target level. The 
recorded HDL (mg/dL) values provided a mean HDL (mg/dL) for females at Baseline of 46.7 
mg/dL. The Post-Program mean HDL was 49.2 mg/dL, which was an insignificant increase of 
2.5 mg/dL (p=0.2815) from Baseline. Although it was statistically insignificant, any increase in 
HDL values from baseline would be considered beneficial. The 1-year Post-Program HDL 
(mg/dL) was 51.3 mg/dL, which was an insignificant increase of 2.1 (p=0.3556) mg/dL from 
Post-Program. However, the increased HDL levels from 49.2 mg/dL at Post-Program to 51.3 
mg/dL at 1-year Post-Program shows that patients reached the target level in the 1-year Post-
program period. The 2-year Post-Program HDL (mg/dL) for females was 52.8 mg/dL, which was 
an insignificant increase of 1.5 mg/dL (p=0.5042) from 1-year Post-Program. Comparing the 
Baseline and 2-years Post-Program HDL (mg/dL) for females, there was a significant increase of 
6.1 mg/dL (p<0.0086). HDL (mg/dL) levels continued to improve through each collection point. 
Females reached the target HDL (mg/dL) range in the 1-year Post-Program point and remained 
32 
 
above the goal through the 2-years Post-Program point, further supporting the success of 
interventions provided.  
      The target recommended HDL (mg/dL) for males with diabetes is >40 mg/dL (Buse et 
al., 2007). The recorded mean HDL (mg/dL) values for males at Baseline were 37.7 mg/dL and 
the Post-Program mean HDL was 40.0 mg/dL, which was statistically insignificant (p=0.1801) 
when compared to baseline, however, the increased HDL value from 37.7mg/dL to 40mg/dL 
shows patients reached the recommendation in the Post-Program period. The 1-year Post-
Program HDL (mg/dL) was 44.4 mg/dL, which was a statistically significant increase of 4.4 
mg/dL (p=0.0448) from Post-Program. The 2-year Post-Program HDL (mg/dL) for males was 
45.0 mg/dL, which was an insignificant increase of 0.6 mg/dL (p=0.8059) from 1-year Post-
Program. Comparing the Baseline and 2-years Post-Program HDL (mg/dL) for males, there was 
a significant increase of 7.3 mg/dL, (p=0.0005). HDL (mg/dL) levels increased from Baseline 
through 2-years Post-Program. Males reached the target HDL (mg/dL) range in the Post-Program 
point and remained above the target range through the 2-years Post-Program point. 
           For the individuals that completed the program, the Baseline mean HDL (mg/dL) was 
43.6 mg/dL. There was an insignificant increase of 2.0 mg/dL (p=0.4158) from Baseline to Post-
Program, which was 45.6 mg/dL. Again, even though the changes were insignificant, increases 
in HDL mg/dL levels would be considered beneficial. The 1-year Post-Program HDL (mg/dL) 
was 49.3 mg/dL, which was an insignificant increase of 3.7 mg/dL (p=0.1436) from Post-
Program. The HDL (mg/dL) for 2-years Post Program for those that completed the program was 
50.2 mg/dL, which was an insignificant increase of 0.9 mg/dL (p=0.7280) from 1-year Post-
Program. Comparing the change from Baseline to 2-years Post-Program there was a significant 
increase in HDL (mg/dL) of 6.6 mg/dL, (p=0.0099), for those that completed the program by 
attending the follow up visit. 
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      For the individuals that did not complete the program, the Baseline mean HDL (mg/dL) 
was 41.2 mg/dL. There was an insignificant increase of 3.1 mg/dL (p=0.0995) from Baseline to 
Post-Program, which was 44.3 mg/dL. The 1-year Post-Program HDL (mg/dL) was 46.7 mg/dL, 
which was an insignificant increase of 2.4 mg/dL (p=0.2437) from Post-Program. The HDL 
(mg/dL) for 2-years Post Program for those that did not complete the program was 48 mg/dL, 
which was an insignificant increase of 1.3 mg/dL (p=0.5463) from 1-year Post-Program. 
Comparing the change from Baseline to 2-years Post-Program there was a significant increase in 
HDL (mg/dL) of 6.8 mg/dL, (p<0.0008), for those that did not complete the program by 
attending the follow up visit. 
           Combining all groups together, including males, females, those that completed the 
program by attending the follow up visit and those that did not, the mean HDL (mg/dL) at 
Baseline was 42.5 mg/dL. There was an insignificant increase of 2.5 mg/dL (p=0.1155) from 
Baseline to Post-Program, which was 45 mg/dL. There was an insignificant increase of 3.1 
mg/dL (p=0.0627) from Post-Program to 1-year Post-Program, which was 48.1 mg/dL. The 2-
year Post-Program mean HDL (mg/dL) for all groups was 49.2 mg/dL, which was an 
insignificant increase of 1.1 mg/dL (p=0.5215) from 1-year Post-Program. Comparing the 
change from Baseline to 2-years Post-Program, there was a significant increase in HDL (mg/dL) 
of 6.7 mg/dL (p<0.0001). The effects of dietary and exercise modifications can be seen in the 
elevations of HDL (mg/dL) levels for all groups throughout each collection point, which can 
result in positive health outcomes.  
Total Cholesterol Values  
      Table 5 presents the mean TC values of each data collection point for gender, program 
completion, and for all groups. There were 116 individuals with TC values collected (n=116). Of 
those 116, 62 (53%) were female and 54 (47%) were male. Table 5 also presents a comparison of 
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TC (mg/dL) levels from Baseline to Post-Program, Post-Program to1-year Post-Program, 1-year 
Post-Program to 2-years Post-Program, and Baseline to 2-years Post-Program for gender, 
program completion, and all groups. Repeated measures of ANOVA showed that patients 
benefitted greatly by receiving education through the SJM Center for Diabetes DSMEP for 
controlling TC (mg/dL) levels. 
Table 5: Reported TC (mg/dL) values for Gender, Program Completion, and all groups at Baseline, Post-Program, 1-year Post-Program, 2-year Post-Program; 
and the t-test comparison of TC (mg/dL) levels from Baseline to Post-Program,  Post-Program to1-year Post-Program, 1-year Post-Program to 2-years Post-
Program, and Baseline to 2-years Post-Program. 
 
Baseline TC 
(mg/dL)      
Mean ± SD 
Post-
Program  
TC (mg/dL)      
Mean ± SD 
Baseline to 
Post-
Program  
p-value 
1-year Post-
Program  
TC (mg/dL)      
Mean ± SD 
Post-
Program to  
1-year  
p-value 
2-years Post-
Program  
TC (mg/dL)      
Mean ± SD 
1-year to  
2-year  
p-value 
Baseline to  
2-year 
p-value 
Gender         
Females (n=62)  191.1 ± 39.6 174.0 ± 34.5 p=0.0116 172.5 ± 32.1 p=0.8025 170.7 ± 32.3 p=0.7561 p=0.0021 
Males (n=54) 182.4 ± 44.0 163.3 ± 39.6 p=0.0195 162.1 ± 37.0 p=0.8711 169.2 ± 45.0 p=0.3725 p=0.1262 
Program Completion a         
Program Completed (n=64)b 184.3 ± 42.7 167.5 ± 39.2 p=0.0220 161.3 ± 35.6 p=0.3507 167.0 ± 43.3 p=0.4175 p=0.0245 
Program Not Completed (n=52)b 190.5 ± 40.7 170.8 ± 34.7 p=0.0092 175.4 ± 32.4 p=0.4863 173.6 ± 31.9 p=0.7759 p=0.0203 
         
TC for all groups (n=116)a, b, c 187.0 ± 41.7 169.0 ± 37.2 p=0.0006 167.7 ± 34.8 p=0.7837 170.0 ± 38.6 p=0.6341 p=0.0015 
         
SD=Standard Deviation         
P is significant at less than .05 
a Program completed as determined by attendance at the follow-up visit.  
b Includes females and males. 
c Includes Program Completed and Not Completed. 
  
 
      The target TC (mg/dL) for people with diabetes is <200 mg/dL (Buse et al., 2007). The 
recorded TC (mg/dL) values provided a mean TC (mg/dL) for females at Baseline of 191.1 
mg/dL. The Post-Program mean TC was 174.0 mg/dL, which was a significant decrease of 17.1 
mg/dL (p=0.0116) from Baseline. The 1-year Post-Program TC (mg/dL) was 172.5 mg/dL, 
which was an insignificant decrease of 1.5 mg/dL (p=0.8025) from Post-Program. The 2-year 
Post-Program TC (mg/dL) for females was 170.7 mg/dL, which was an insignificant decrease of 
1.8 mg/dL (p=0.7561) from 1-year Post-Program. Comparing the Baseline and 2-years Post-
Program TC (mg/dL) for females, there was a significant decrease of 20.4 mg/dL (p=0.0021). 
Total Cholesterol (mg/dL) levels continued to decline through each collection point. Females 
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were below the target TC (mg/dL) range at baseline and remained below the target range through 
the 2-years Post-Program point, suggesting that the SJM Center for Diabetes DSMEP is effective 
at maintaining TC levels below the target range.  
      The recorded TC (mg/dL) values provided a mean TC (mg/dL) for males at Baseline of 
182.4 mg/dL. The Post-Program mean TC was 163.3 mg/dL, which was a significant decrease of 
19.1 mg/dL (p=0.0195) from Baseline. The 1-year Post-Program TC (mg/dL) was 162.1 mg/dL, 
which was an insignificant decrease of 1.2 mg/dL (p=0.8711) from Post-Program. The 2-year 
Post-Program TC (mg/dL) for males was 169.2 mg/dL, which was an insignificant increase of 
7.1 mg/dL (p=0.725) from 1-year Post-Program. Comparing the Baseline and 2-years Post-
Program TC (mg/dL) for males, there was an insignificant decrease of 13.2 mg/dL (p=0.1262). 
TC (mg/dL) levels declined from Baseline through 1-year Post-Program and then showed an 
increase at 2 years Post-Program. Even though the TC (mg/dL) levels increased slightly at the 2-
year Post-Program point, males remained below the target range from Baseline through the 2-
years Post-Program.  
           For the individuals that completed the program, the Baseline mean TC (mg/dL) was 
184.3 mg/dL. There was a significant decrease of 16.8 mg/dL (p=0.0220) from Baseline to Post-
Program, which was 167.5 mg/dL. The 1-year Post-Program TC (mg/dL) was 161.3 mg/dL, 
which was an insignificant decrease of 6.2 mg/dL (p=0.3507) from Post-Program. The TC 
(mg/dL) for 2-years Post Program for those that completed the program was 167 mg/dL, which 
was an insignificant increase of 5.7 mg/dL (p=0.4175) from 1-year Post-Program. Comparing the 
change from Baseline to 2-years Post-Program there was a significant decrease in TC (mg/dL) of 
17.3 mg/dL (p=0.0245), for those that completed the program by attending the follow up visit, 
and all collection points were below the target range for TC (mg/dL). 
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       For the individuals that did not complete the program, the Baseline mean TC (mg/dL) 
was 190.5 mg/dL. There was a significant decrease of 19.7 mg/dL (p=0.0092) from Baseline to 
Post-Program, which was 170.8 mg/dL. The 1-year Post-Program TC (mg/dL) was 175.4 mg/dL, 
which was an insignificant increase of 4.6 mg/dL (p=0.4863) from Post-Program. The TC 
(mg/dL) for 2-years Post Program for those that did not complete the program was 173.6 mg/dL, 
which was an insignificant decrease of 1.8 mg/dL (p=0.7759) from 1-year Post-Program. 
Comparing the change from Baseline to 2-years Post-Program there was a significant decrease in 
TC (mg/dL) of 16.9 mg/dL (p=0.0203), for those that did not complete the program by attending 
the follow up visit, and again, all Post-Program points were again below the target range for TC 
(mg/dL).  
           When looking at all groups together, including males, females, those that completed the 
program by attending the follow up visit and those that did not, the mean TC (mg/dL) at Baseline 
was 187 mg/dL. There was a significant decrease of 18 mg/dL (p=0.0006) from Baseline to Post-
Program, which was 169 mg/dL, suggesting that the SJM Center for Diabetes DSMEP is 
effective at lowering TC levels. There was an insignificant decrease of 1.3 mg/dL (p=0.7837) 
from Post-Program to 1-year Post-Program, which was 167.7 mg/dL. The 2-year Post-Program 
mean TC (mg/dL) for all groups was 170 mg/dL, which was an insignificant increase of 2.3 
mg/dL (p=0.6341) from 1-year Post-Program. Comparing the change from Baseline to 2-years 
Post-Program, there was a significant decrease in TC (mg/dL) of 17 mg/dL (p=0.0015). The 
mean TC (mg/dL) for all groups was below the target of 200 mg/dL in all of the collection 
points, again showing significant improvements in TC (mg/dL). The TC levels for all groups 
remained below the target level from Baseline through 2-years Post-Program again supporting 
the success of education interventions at maintaining TC levels below the target range.  
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Chapter 5: Discussion 
Question One: Is the SJM Center for Diabetes DSMEP effective at lowering and/or 
maintaining lowered HbA1c levels at one year and two years after receiving education? 
Previous data collected on the SJM Center for Diabetes DSMEP supports the effectiveness of the 
program by demonstrating lowered HbA1c levels in individuals that attended the education 
classes (Karolle, 2011). Previous studies have also shown that the DSMEP can be a cost-
effective method of maintaining glycemic control when compared with individuals who do not 
receive diabetes education (Li et al., 2010). The results of this study further support the 
effectiveness of the SJM Center for Diabetes DSMEP by reporting a significant decrease in 
HbA1c levels of 1.63% from the time an individual enters the program (Baseline) to the time that 
they complete the education classes (Post-Program).  
           The results also support a positive answer to the question of whether the SJM Center for 
Diabetes DSMEP is effective at maintaining lowered HbA1c levels at one and two years after 
receiving education services. Individuals in this study received services in 2010. Results from the 
Post-Program to 1-year Post-Program (2011) showed there was a modest but insignificant 
increase in mean HbA1c levels of 0.16%. There was again a slight, but insignificant increase in 
mean HbA1c levels from 1-year Post-Program to 2-years Post-Program of 0.07%, suggesting 
that the mean HbA1c levels stabilize and the slight trend upward was at a slower rate. While 
there were increases in HbA1c levels from the Post-Program to 1-year Post-Program and 2-years 
Post-Program, it is important to note that the mean HbA1c levels for all three Post-Program 
collection points were below the recommended HbA1c level for people with T2DM of 7.0% 
(ADA, 2011). The slight, but trending rise in HbA1c levels from the subsequent years may 
indicate a need for continued follow-up for each year after the initial education program, 
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however, further long-term studies with HbA1c levels will determine if the follow-up visits have 
a positive impact.  
      The results show the mean HbA1c level is lower, overall, in individuals who complete 
the program, though not to a significant degree. Further studies may indicate whether this is due 
to the education program, or the likelihood of general increased compliance in the group that 
completes the program.   
      Question Two: Is the SJM Center for Diabetes DSMEP effective at lowering and/or 
maintaining lowered lipid levels at one year and two years after receiving education? 
This study provided some mixed results therefor it is necessary to review each of the lipid values 
separately. 
      Mean LDL levels for all groups from Baseline were 112.5 mg/dl and significantly 
decreased to 97.2 mg/dl at the Post-Program collection point. LDL levels continued to decrease 
from Post-Program to 1-Year Post-Program, and 2-years Post-Program. All of the post program 
levels were below the recommended LDL level of 100 mg/dl (Buse, 2007) and continued to 
trend lower from year to year. Therefore, LDL levels were initially lowered, and then were 
sustained throughout each of the data collection points.  
      LDL levels were not significantly different between genders. They were slightly higher in 
women, which may be a result of cholesterol levels rising as women age, increasing during and 
after menopause, associating the increased risk for CVD in women (Papdopoulou & Kaski, 
2013). LDL levels continued to decrease from Post-Program to 1-year-Post Program and 2-years 
Post-Program for females. Males showed an initial decrease from Baseline to Post-Program, and 
from Post-Program to 1-year Post-Program. LDL levels began to rise insignificantly from 1-year 
Post-Program to 2-Years Post-Program.  
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      The mean LDL levels were not significantly different between those that completed the 
program from those that only completed the nine-hours of classroom education. The group that 
completed the program had slightly lower LDL levels, but not to a significant degree. Again, 
further research will determine if this slight difference is related to increased compliance overall 
in the individuals who completed the program. 
      HDL levels showed no significance in change from Baseline to Post-Program for all 
groups. The levels did increase from Baseline to Post-Program, as well as from Post-Program to 
1-year Post-Program, and again from 1-year Post-Program to 2-years Post-Program. While these 
levels trended higher throughout each of the data collection points, none of the changes were 
reported as significant; however, it is also essential to report that females and males reached their 
target HDL level. 
      HDL levels in all of the data collection points were significantly higher for women than 
for men. This may be attributed to the naturally occurring increased cholesterol levels in women 
throughout the study (Papdopoulou & Kaski, 2013). The combined gender mean HDL levels 
trended upward consistently from year to year. The target levels for HDL cholesterol are >40 
mg/dL for men and >50 mg/dL for women (Buse, 2007). When looking at the differences for 
men and women, men met their target level in the Post-Program data collection point of 40.0 
mg/dL and remained above target level into 1-year and 2-years Post-Program with 44.4mg/dL 
and 45.0 mg/dL. Women reached their target HDL level at 1-year Post-Program and remained in 
target at 2-Years Post-Program, with 51.3 mg/dl and 52.8 mg/dl respectively. Although there 
were no significant changes in HDL levels from Baseline to Post-Program between genders, 
whether the program was completed or not, and for all groups, it is important to note that the 
HDL levels continued to trend higher throughout each of the data collection points.  
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      Total Cholesterol  levels for all groups were below the goal of <200 mg/dl and remained 
below goal for the duration of the study (Buse, 2007). From Baseline to Post-Program, there was 
a significant decrease in mean TC levels of 18.0 mg/d. The TC levels for all groups decreased 
slightly and insignificantly, from Post-Program to 1-year Post-Program. The levels increased 
insignificantly from 1-year Post-Program to 2-years Post-Program. The insignificant change in 
TC levels suggest that they remained relatively stable after the initial lowering from Baseline to 
Post-Program.               
      TC levels were overall lower for men than women, this again may be attributed to the 
natural rise in cholesterol levels as women age, similar to the LDL and HDL levels 
(Papdopoulou & Kaski, 2013). TC levels continued to decrease from Post-Program to 1-year-
Post Program and 2-years Post-Program for females. Males showed an initial decrease from 
Baseline to Post-Program, and from Post-Program to 1-year Post-Program. TC levels began to 
rise insignificantly from 1-year Post-Program to 2-Years Post-Program. This is a similar trend 
found in LDL cholesterol levels between genders. Further research will be needed to determine if 
there is any significance to this trend, and how it may further the advancement in reducing risks 
on heart disease for women and men. 
      The results from the lipid values suggest that the SJM Center for Diabetes DSMEP is an 
effective adjunct to a comprehensive therapy program in lowering and maintaining lowered LDL 
and TC levels, while increasing and maintaining increased HDL levels at 1 and 2-years 
following the program. These improved lipid levels can be instrumental in reducing 
macrovascular disease, as opposed to just HbA1c levels alone. Longer-term lipid values like 
these may also shed more light on the legacy effect discussed in the UKPDS (UKPDS, 1999) and 
EDIC (Nathan et al., 2005) studies for the long-term reduction in macrovascular disease.  
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Application to Practice 
      The UKPDS and the 10-year follow up showed that improvements in glycemic control 
could help reduce microvascular and macrovascular complications related to T2DM (Holman et 
al., 2008). The patients in the UKPDS studies received dietary and/or pharmacological 
interventions. The more recent ADVANCE (ADVANCE, 2008) trial also suggests that these 
interventions may continue to help reduce microvascular complications, and the results of the 
ADVANCE-ON follow up study may show similar promise for macrovascular complications if 
the legacy effect is true, which could reproduce results similar to the UKPDS 10-year follow-up 
study (Holman et al., 2008; ADVANCE, 2008; Hamet, 2012). Continued long-term 
observational studies on patients that enter the SJM Center for Diabetes DSMEP would be 
helpful in determining additional complication reduction potential.  
      The ACCORD study’s intensive arm was halted because aggressive intervention with 
medications was shown to increase mortality in high-risk, elderly patients with T2DM 
(ACCORD, 2011).  The participants in this study receive both educational and pharmacological 
interventions. Similarly, the VADT study did not yield any positive results for intensive therapy 
on microvascular and macrovascular outcomes (Duckworth, 2009). This high risk, elderly 
population may benefit more from programs like SJM Center for Diabetes DSMEP, where the 
focus is on lifestyle instead of intensive control from pharmacological agents. Given the mean 
age of the study population of 64, it is possible that many individuals who enter the SJM Center 
for Diabetes DSMEP could fall under these characteristics and would likely be inappropriate for 
intensive therapy.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
Program Planning  
Program planning decisions are based on health outcomes of the patients, including 
HbA1c level reduction. Once the nine hours of education classes are complete, there is only one 
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follow-up visit planned, which is typically three to six weeks after the classes are completed. If 
the patient does not attend that follow-up visit, the program is incomplete, and no further follow-
up occurs. Those that completed the program had overall improved levels in every category 
when compared to those that did not complete the program. Considering the slight, but 
significant increases in HbA1c levels and slight but insignificant increase in TC levels from Post-
Program to 1-year Post-Program and 2-years Post-Program, regularly continued follow-up visits 
may result in maintained lowered HbA1c and lipid levels. Piloted follow-up visits with data 
collection and analysis would be helpful in determining if regular post-program follow-up visits 
would prevent any increase in HbA1c and TC levels.  
      Given the effectiveness of the SJM Center for Diabetes DSMEP, physician offices who 
are changing to the PCMH model may continue to rely on the DSMEP to help patients reach 
target health outcomes. As the climate of health care continues to change, it is important to keep 
patient care at the forefront of any model. As health care reimbursement changes, the SJM 
Center for Diabetes DSMEP may continue to be a cost-effective way of delivering much needed 
education and support to individuals with diabetes. 
Limitations of this Study 
      There were several variables not controlled for in this study include pharmacotherapy 
agents prescribed by the patient’s physician, barriers to receiving services, and education or 
information received by other means. These variables require acknowledgement as possible 
contributors to compliance with lifestyle changes and increased blood glucose and lipid control.  
      The data collected on study participants may be affected by pharmacotherapy agents 
prescribed by the patient’s physician. Understanding that the DSME is often an adjunct therapy 
to pharmacotherapies prescribed by physicians, the goal is to help reduce microvascular and 
macrovascular complications by decreasing the modifiable risk factors by all therapies necessary, 
43 
 
which may result in multiple concomitant therapies used, including the DSMEP (McCance, 
2009).  
      This study reports a benefit from attending the SJM Center for Diabetes DSMEP; 
however, participants in the DSMEP may have had fewer barriers to self-care and more likely to 
improve their HbA1c and lipid levels. Barriers may be economical, physical, psychological, 
cultural, or social in nature. Barriers may affect an individual’s compliance to pharmacological 
therapy, behavior modification, and overall self-care. Individuals with difficult or multiple 
barriers may be less likely to attend a DSMEP. Some specific barriers may have been addressed 
individually, however are not accounted for in the scope of this study. 
      Patients may receive education or find information from multiple sources around them 
including the primary physician’s office, endocrinologist’s office, friends, family, as well as the 
abundance of information found on the internet when using reputable sources. Patients may also 
receive the emotional or social support needed to make necessary changes, overall affecting 
HbA1c and lipid values. 
      Not all laboratory values were available in the electronic medical record; values collected 
were obtained at the discretion of the individual’s physician. Individuals who have regular 
primary care appointments and laboratory values may be more likely to be successful in other 
self-management behaviors. St. Joseph Mercy Center for Diabetes does not collect any blood 
samples to address any missing data that would be helpful in assessing long-term effectiveness.  
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Chapter 6: Conclusions 
Conclusions 
      The results of this study show that the SJM Center for Diabetes DSMEP is effective as 
part of a comprehensive therapy program in lowering HbA1c levels in people with diabetes from 
the time an individual enters the program to the end of the program. The results of this study also 
suggest that the SJM Center for Diabetes DSMEP is effective at improving LDL and TC levels 
from the beginning to the end of the program. Furthermore, the SJM Center for Diabetes 
DSMEP appears to be effective in sustaining improvements of HbA1c, LDL, HDL, and TC for at 
least two years after services were provided. There were no significant differences between the 
group that completed the program versus the group that did not complete the program, however 
in each of the data collection points there was a trend toward improvement for those who did 
complete the program. It is unknown whether this difference is related to the program, or other 
general compliance factors. The reductions in HbA1c percent and improvements in lipid levels 
are correlated with improved health outcomes in individuals with diabetes (ADA, 2011; 
McCance, 2009; Funnell, 2007), which is the main goal in providing diabetes education self-
management programs. The results of this study further support the evidence suggesting that 
individuals with diabetes who attend a DSME program have better glycemic control, as well as 
improved lipid profiles, higher quality of life, and increased knowledge and understanding about 
diabetes and self-management skills (Brennan, Hwang, &Phelps, 2011; Khanna et al, 2012). 
Implications for Saint Joseph Mercy Center for Diabetes  
      The current content of the SJM Center for Diabetes DSMEP covers not only methods to 
obtain and maintain optimal glucose levels, it also covers methods to obtain and maintain 
optimal lipid levels. The results from this study support the continued use of the current 
curriculum, updated regularly as new evidence-based material comes available. The slight 
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increase at one and two years in HbA1c and TC levels and the long-term intervention required to 
positively impact microvascular and macrovascular complications suggest a need for continued 
follow-up consisting of education and support in years following the initial education program. 
Long-term studies suggest a sustained benefit from initial interventions; however, microvascular 
and macrovascular risks may further be lowered from continued contact with the DSMEP. 
Future Research 
      Future research could continue in a similar manner at SJM Center for Diabetes. The 
current Microsoft Access database used contains only pre and post program HbA1c levels that 
are available in PowerChart
TM
 at the time the patient chart is audited and closed. Lipid values 
may be available and could be collected at the same time as the HbA1c by the clinician. If 
patients have continued follow-up visits at the SJM Center for Diabetes, the appropriate changes 
to the database could be made to capture this ongoing data as the patient returns for follow-ups. 
Annual queries are made in the database to evaluate pre- and post-program HbA1c levels; 
queries could be made at the same time to evaluate lipid levels.  
      As more physicians are using the EMR, more laboratory values will become available. 
As patients continue to follow-up with the SJM Center for Diabetes, longer-term data will 
become available. This data may be helpful in assessing long-term microvascular and 
macrovascular risk reductions associated with the SJM Center for Diabetes DSMEP. 
      Further studies that could be done within the SJM Center for Diabetes could be looking at 
the changes in HbA1c and lipid levels in the individuals that do not attend all of the education 
classes, or for the individuals that come in for one visit and do not return. Studies in this area 
could review the effectiveness of the initial contact point.  
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      Another area of study could be the comparison of the DSMEP to the education received 
in the physician’s office. This may be an important area to study with the increased use of the 
PCMH, where more education is likely to be provided in the primary care setting.  
      An important undertaking will be in defining the numerous barriers that may be 
preventing individuals from attending or completing the education program, or taking part in 
basic diabetes self-care management. Understanding and addressing these barriers will aid in the 
development of strategies to overcome or manage them, while ultimately improving the level of 
glucose control and reducing overall health risks.  
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Appendix 2 – Eastern Michigan University College of Health and Human Services Human 
Subjects Approval 
 
Date: Tue Apr 16 2013 
Subject: MS #1116 - College of Health and Human Services Human Subjects  
From: Gretchen Dahl Reeves  
Decision: Accept Submission  
 
Dear Clisty, 
 
Congratulations! After careful review, your proposal "The Effectiveness of The St. Joseph Mercy Center for Diabetes 
Education Program  at 1 and 2 years Post Program Completion." has been approved by the College of Health and 
Human Services Human Subjects committee. We stress that you do not stray from your proposed plan. Good luck 
with your research effort. 
 
 
The current version of your paper is available here: 
http://commons.emich.edu/cgi/preview.cgi?article=1116&context=chhs_hs 
 
Sincerely, 
 
Gretchen Dahl  Reeves, PhD 
Chair, CHHS-HSRC 
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Appendix 4 – The SJM Center for Diabetes program outline. 
Saint Joseph Mercy Center for Diabetes 
Diabetes Self-Care Education Program   
 
Family members and other support people are encouraged to attend with you.  Please feel free to 
bring food or a drink with you. 
 
First Visit 
 Health History 
 Diet History 
 Meal Plan 
 
Class #1. Diabetes Skills (3 hours) 
**Bring glucometer and supplies to this class 
 Meal Planning 
 Medications 
 Low Blood Sugar 
 Blood Sugar Monitoring 
 
Class #2. Diabetes Overview and Long Term Care for Diabetes (3 hours) 
 What is Diabetes? 
 Exercise 
 High Blood Sugar 
 Sick Day Management 
 Diabetes Complications 
 Hygiene and Foot Care 
 Community Resources 
 
Class #3. Nutrition for Diabetes (3 hours) 
Disease Prevention 
Dining Out 
Sweeteners 
Label Reading 
Goal Setting 
 
Last Visit (1/2 hour with dietitian,1/2 hour with nurse) 
**Bring glucometer and blood sugar records to this visit 
 Review of meter, blood sugar records, meal plan and exercise plan 
 Behavior Goals 
 Foot Care and Foot Exam 
 
Ann Arbor classes are held Thursdays 5-8pm and Fridays 9am-12pm. Livingston classes are held 
Thursdays 1-4pm and 5-8pm. Registration is required. Please call us at (734) 712-1313 to 
schedule. 
 
 
